Sign up Australia
Proactive Investors - Run By Investors For Investors

The Hydroponics Company makes key appointment following medical cannabis partnership

Debbie Ormsby will lead Canndeo to fast-track medicinal cannabis products into Australia.
The Hydroponics Company makes key appointment following medical cannabis partnership
THC shares have increased five-fold to over $1 since listing in May

The Hydroponics Company Ltd (ASX:THC) has appointed the experienced Debbie Ormsby as chief commercial officer. 

Ormsby brings significant pharmaceutical and biotech expertise with extensive experience in end to end product commercialisation within the pharmaceutical markets.

The appointment follows the company's wholly-owned subsidiary, Canndeo Limited, locking in off-shore supply of medicinal cannabis by entering into a partnership with BOL Pharma.

READ NOW: The Hydroponics Company in company making partnership with Israel's BOL Pharma

BOL Pharma is one of Israel’s leading medicinal cannabis producers.

View full THC profile View Profile

The Hydroponics Company Timeline

Related Articles

researcher filling a vial
May 29 2018
ImmuPharma chairman Tim McCarthy said: "We continue to believe Lupuzor has the potential to bring a much needed treatment to Lupus sufferers around the world"
cancer cells in blood
Tue
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
1519933435_to-conceive-pic.jpg
March 01 2018
The health and wellbeing group, which has a broad product portfolio, had an eventful 2017,

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use